AD80, a multikinase inhibitor, as a potential drug candidate for colorectal cancer therapy (2022)
- Authors:
- USP affiliated authors: MACHADO NETO, JOÃO AGOSTINHO - ICB ; LOTUFO, LETICIA VERAS COSTA - ICB ; ALMEIDA, LARISSA COSTA DE - ICB ; CARLOS, JORGE ANTONIO ELIAS GODOY - ICB ; TEIXEIRA, PAULA REZENDE - ICB
- Unidade: ICB
- DOI: 10.1016/j.lfs.2022.120911
- Subjects: FARMACOLOGIA; NEOPLASIAS COLORRETAIS; PROTEÍNAS PROTO-ONCOGÊNICAS; RNA MENSAGEIRO; APOPTOSE; ANTINEOPLÁSICOS; CÉLULAS CULTIVADAS DE TUMOR; INIBIDORES DE ENZIMAS; ATIVAÇÃO ENZIMÁTICA; PROTEÍNAS QUINASES; TRANSDUÇÃO DE SINAL CELULAR; CARCINOGÊNESE; PROLIFERAÇÃO CELULAR
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Publisher place: Philadelphia
- Date published: 2022
- Source:
- Título do periódico: Life Sciences
- ISSN: 1879-0631
- Volume/Número/Paginação/Ano: v. 308, art. 120911, p. 1-9, 2022
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: bronze
- Licença: publisher-specific-oa
-
ABNT
ALMEIDA, Larissa Costa de et al. AD80, a multikinase inhibitor, as a potential drug candidate for colorectal cancer therapy. Life Sciences, v. 308, p. 1-9, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.lfs.2022.120911. Acesso em: 20 set. 2024. -
APA
Almeida, L. C. de, Carlos, J. A. E. G., Teixeira, P. R., Machado Neto, J. A., & Costa-Lotufo, L. V. (2022). AD80, a multikinase inhibitor, as a potential drug candidate for colorectal cancer therapy. Life Sciences, 308, 1-9. doi:10.1016/j.lfs.2022.120911 -
NLM
Almeida LC de, Carlos JAEG, Teixeira PR, Machado Neto JA, Costa-Lotufo LV. AD80, a multikinase inhibitor, as a potential drug candidate for colorectal cancer therapy [Internet]. Life Sciences. 2022 ; 308 1-9.[citado 2024 set. 20 ] Available from: https://doi.org/10.1016/j.lfs.2022.120911 -
Vancouver
Almeida LC de, Carlos JAEG, Teixeira PR, Machado Neto JA, Costa-Lotufo LV. AD80, a multikinase inhibitor, as a potential drug candidate for colorectal cancer therapy [Internet]. Life Sciences. 2022 ; 308 1-9.[citado 2024 set. 20 ] Available from: https://doi.org/10.1016/j.lfs.2022.120911 - DNA damaging agents and DNA repair: from carcinogenesis to cancer therapy
- Purine-derived phenylhydroxamate compounds reduce cell viability and modulate HDAC activity in hematological neoplasm models
- What can we learn from commercial insecticides? Efficacy, toxicity, environmental impacts, and future developments
- Purine-derived Phenylhydroxamate compounds induces cell death in hematological neoplasm models
- ANKHD1 contributes to the malignant phenotype of triple-negative breast cancer cells
- Novel [6]-gingerol triazole derivatives and their antiproliferative potential against tumor cells
- Seriniquinones as therapeutic leads for treatment of BRAF and NRAS mutant melanomas
- Antitumoral activity of different Amaryllidaceae alkaloids: in vitro and in silico assays
- Isolation, Absolute Configuration and Cytotoxic Activities of Alkaloids from Hippeastrum goianum (Ravenna) Meerow (Amaryllidaceae)
- Nanofibers of Jussara Pulp: a tool to prevent the loss of thermal stability and the antioxidant activity of anthocyanins after simulated digestion
Informações sobre o DOI: 10.1016/j.lfs.2022.120911 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
